155 related articles for article (PubMed ID: 20522379)
1. Safety and efficacy of denosumab in giant-cell tumour of bone.
Kyrgidis A; Toulis K
Lancet Oncol; 2010 Jun; 11(6):513-4. PubMed ID: 20522379
[No Abstract] [Full Text] [Related]
2. Safety of denosumab in giant-cell tumour of bone.
Thomas D; Carriere P; Jacobs I
Lancet Oncol; 2010 Sep; 11(9):815. PubMed ID: 20816372
[No Abstract] [Full Text] [Related]
3. Denosumab: a breakthrough in treatment of giant-cell tumour of bone?
Balke M; Hardes J
Lancet Oncol; 2010 Mar; 11(3):218-9. PubMed ID: 20149737
[No Abstract] [Full Text] [Related]
4. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
Thomas D; Henshaw R; Skubitz K; Chawla S; Staddon A; Blay JY; Roudier M; Smith J; Ye Z; Sohn W; Dansey R; Jun S
Lancet Oncol; 2010 Mar; 11(3):275-80. PubMed ID: 20149736
[TBL] [Abstract][Full Text] [Related]
5. Denosumab for bone metastases from breast cancer: a new therapy option?
Aapro MS
J Clin Oncol; 2011 May; 29(14):e419-20; author reply e421-4. PubMed ID: 21464408
[No Abstract] [Full Text] [Related]
6. Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.
Fusco V; Galassi C; Berruti A; Ciuffreda L; Ortega C; Ciccone G; Angeli A; Bertetto O
J Clin Oncol; 2011 Jun; 29(17):e521-2; author reply e523-4. PubMed ID: 21537047
[No Abstract] [Full Text] [Related]
7. RANKL, denosumab, and giant cell tumor of bone.
Thomas DM
Curr Opin Oncol; 2012 Jul; 24(4):397-403. PubMed ID: 22581354
[TBL] [Abstract][Full Text] [Related]
8. More about osteonecrosis.
Finkelman RD; Clemons M; Bouganim N
J Am Dent Assoc; 2011 Apr; 142(4):371-2; author reply 372-4. PubMed ID: 21454842
[No Abstract] [Full Text] [Related]
9. Denosumab-related osteonecrosis of the jaws.
Kyrgidis A; Toulis KA
Osteoporos Int; 2011 Jan; 22(1):369-70. PubMed ID: 20306021
[No Abstract] [Full Text] [Related]
10. Denosumab for bone metastases.
Med Lett Drugs Ther; 2011 Jan; 53(1356):8. PubMed ID: 21252843
[No Abstract] [Full Text] [Related]
11. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of jaw with the use of denosumab.
Akhtar NH; Afzal MZ; Ahmed AA
J Cancer Res Ther; 2011; 7(4):499-500. PubMed ID: 22269422
[No Abstract] [Full Text] [Related]
13. A new class of drugs to prevent osteoporosis may be associated with osteonecrosis of the jaw.
Wynn RL
Gen Dent; 2011; 59(1):10-2. PubMed ID: 21613033
[No Abstract] [Full Text] [Related]
14. Denosumab an option for patients with bone metastasis from breast cancer.
Barton MK
CA Cancer J Clin; 2011; 61(3):135-6. PubMed ID: 21532096
[No Abstract] [Full Text] [Related]
15. Denosumab: Excellent response of metastatic giant cell tumor of the bone.
Ulas A; Bulent Akinci M; Silay K; Sendur MA; Sener Dede D; Yalcin B
J BUON; 2015; 20(2):666-7. PubMed ID: 26011370
[No Abstract] [Full Text] [Related]
16. Denosumab: a new treatment option for giant cell tumor of bone.
Lewin J; Thomas D
Drugs Today (Barc); 2013 Nov; 49(11):693-700. PubMed ID: 24308016
[TBL] [Abstract][Full Text] [Related]
17. New oncology drugs and osteonecrosis of the jaw (ONJ).
Migliorati CA; Covington JS
J Tenn Dent Assoc; 2009; 89(4):36-8; quiz 38-9. PubMed ID: 20102031
[No Abstract] [Full Text] [Related]
18. Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone.
Demirsoy U; Karadogan M; Selek Ö; Anik Y; Aksu G; Müezzinoglu B; Corapcioglu F
J Pediatr Hematol Oncol; 2014 Mar; 36(2):156-8. PubMed ID: 24072245
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
Chawla S; Henshaw R; Seeger L; Choy E; Blay JY; Ferrari S; Kroep J; Grimer R; Reichardt P; Rutkowski P; Schuetze S; Skubitz K; Staddon A; Thomas D; Qian Y; Jacobs I
Lancet Oncol; 2013 Aug; 14(9):901-8. PubMed ID: 23867211
[TBL] [Abstract][Full Text] [Related]
20. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
Gossai N; Hilgers MV; Polgreen LE; Greengard EG
Pediatr Blood Cancer; 2015 Jun; 62(6):1078-80. PubMed ID: 25556556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
